GlaxoSmithKline's June announcement that it was cutting 350 jobs worldwide is coming to fruition. The company just laid off 22 scientists at its Medicinal Chemistry and Oncology Department in Research Triangle Park, North Carolina. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments